Skip to main content
Top

Clinical and Translational Oncology

Issue 6/2014

Content (11 Articles)

Educational Series - Blue Series

Cancer cell resistance mechanisms: a mini review

S. Al-Dimassi, T. Abou-Antoun, M. El-Sibai

EDUCATIONAL SERIES—RED SERIES

Lung cancer in women: an overview with special focus on Spanish women

J. Remon, E. Molina-Montes, M. Majem, P. Lianes, D. Isla, P. Garrido, E. Felip, N. Viñolas, J. de Castro, A. Artal, M.-J. Sánchez

Research Article

Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients

A. Sánchez-Muñoz, Y. Plata-Fernández, M. Fernández, A. Jaén-Morago, M. Fernández-Navarro, C. de la Torre-Cabrera, C. Ramirez-Tortosa, J. Pascual, E. Alba, P. Sánchez-Rovira

Research Article

Final results of a phase II single-institutional trial with hyperfractionated radiation therapy (HFX) and four-weekly continuous cisplatin in locally advanced head and neck carcinoma

F. Arias, G. Asín, M. I. Uzcanga, E. Maraví, I. Quílez, V. Chicata, C. Eito, A. Viudez, I. Hernández, F. Mañeru, M. A. Domínguez

Research Article

Peroxiredoxin 3 is resistant to oxidation-induced apoptosis of Hep-3b cells

Y.-G. Wang, L. Li, C.-H. Liu, S. Hong, M.-J. Zhang

Research Article

Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts

L. Wang, X. Huang, X. Zheng, X. Wang, S. Li, L. Zhang, Z. Yang

Research Article

Post-chemoradiation anastomotic recurrence in locally advanced rectal cancer: no increased risk associated with distal margin

F. A. Calvo, F. Rivas, C. V. Sole, M. Gómez-Espí, R. Herranz, E. del Valle, M. Rodríguez, E. Álvarez

Research Article

Identification of the methylation of p14ARF promoter as a novel non-invasive biomarker for early detection of lung cancer

L. Li, Y. Shen, M. Wang, D. Tang, Y. Luo, W. Jiao, Z. Wang, R. Yang, K. Tian

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine